Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study
Cynthia Levy(University of Miami), Alexandra Steinberg(CymaBay Therapeutics (United States)), Elena Muslimova, Wendy Chen(The University of Texas MD Anderson Cancer Center), Marlyn J. Mayo(Southwestern Medical Center), Mitchell L. Shiffman(Bon Secours Health System), Klara Dickinson, Christoph Berg(University of Cologne), John M. Vierling(Baylor College of Medicine), Sandrin C. Bergheanu, Aliya Gulamhusein(Toronto General Hospital), Aparna Goel(Stanford University), Charles Landis(University of Washington), Gideon M. Hirschfield(University Health Network), Christopher L. Bowlus(University of California, Davis), Richard Aspinall(Queen Alexandra Hospital), Adam Peyton, Tarek Hassanein, Charles A. McWherter(University Health Network), Stuart C. Gordon(United States Department of Veterans Affairs), Frances Seput-Dingle, Marcus-Alexander Woerns, Pol Boudes(CymaBay Therapeutics (United States)), Paul J. Thuluvath(University of Maryland, Baltimore), Palak Trivedi(University Hospitals Birmingham NHS Foundation Trust), Lily Mao, David C. Sheridan, Lynsey Corless(University of Hull), Peter Buggisch(Institute for Interdisciplinary Medicine), Andreas E. Kremer(Friedrich-Alexander-Universität Erlangen-Nürnberg), Mark G. Swain(University of Calgary), Joseph A. Odin(University of Pittsburgh), Carmen Stanca, David I. Bernstein(Cincinnati Children's Hospital Medical Center), Stephen A. Harrison(Pinnacle Clinical Research), Yu Li(China Medical University), Mónika Varga(CymaBay Therapeutics (United States)), Yun‐Jung Choi(CymaBay Therapeutics (United States)), David Jones(Memorial Sloan Kettering Cancer Center), Brian B. Borg(National Institute of Diabetes and Digestive and Kidney Diseases), Guy Neff, Bruce R. Bacon(Saint Louis University), Yvonne Döerffel(Charité - Universitätsmedizin Berlin), Ke Yang(Northwestern Polytechnical University), Galambos Michael, Douglas Thorburn(Royal Free London NHS Foundation Trust)
Cited by 10
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k